With about 500 biotech companies registered, The Netherlands remain one of the strongest Life Science markets in Europe. The number of biotechs newly founded in 2018 was not as high as in previous years but the region is very far from stagnation. According to the data gathered in Biotechgate, over 100 million USD of venture capital was invested in Dutch biotech companies last year. The largest round – 30 mln USD, series B – was secured by Xenikos B.V., a clinical-stage biopharmaceutical company working on a novel therapy for treating acute graft-versus-host disease (aGVHD).
Would you like to be notified about new reports and other valuable content published by Biotechgate?